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1. Introduction  
Coronary artery disease (CAD) is one of the leading causes of death worldwide and it is 
expected that the rate of CAD will accelerate in the next decade due to overall aging of 
population and increases in the prevalence of cardiovascular risk factors (type 2 diabetes, 
obesity, metabolic syndrome) in younger generations (Amborsioni et al., 2003). The 
mortality associated with atherosclerotic disease is mainly related to the acute coronary 
syndromes (ACS), including acute myocardial infarction (AMI), unstable angina (UA) 
pectoris and sudden cardiac death. Inflammation plays a central role throughout the entire 
disease progression, and it lies at the root of atherosclerosis initiation, progression and its 
complications (Bonow et al., 2002).  
However, recent data support the notion that plaques within the coronary circulation 
become “more severe” or at “high-risk” (vulnerable plaque) in response to a wide array of 
local and systemic influences, both inflammatory and non-inflammatory (Alsheikh-Ali et al., 
2010; Finn AV et al., 2010). Indeed, plaques may have similar structural features and 
morphologic assessment, but may differ in their biology, their activity, and thus their 
likelihood of advancing toward clinical complications. Advances in the understanding of 
the pathogenesis of coronary atheroslcerosis have stimulated development of novel 
biomarkers, and expanded their role in the different spectra of their underlying 
pathophysiology (Hochholzer et al., 2010). In this regard, an emerging approach is 
represented by the assessment of plaque burden, morphology, and remodeling with in vivo 
atherosclerosis imaging and its correlation to novel biomarkers (Prati & Zimarino, 2010). 
In the past, invasive coronary angiography (CAG) has been the only diagnostic procedure 
for identifying coronary atherosclerosis. However, newer intracoronary imaging modalities 
have been developed allowing a more accurate and precise evaluation of coronary 
atherosclerotic lesions, with regard to specific morphologic criteria, especially concerning 
vulnerability. Intravascular ultrasound (IVUS) is a catheter-based technology that allows for 
assessment of vessel wall thickness and structure while coronary angioscopy also allows to 
visualize the vessel lumen (Kaneda et al., 2010). More recently, optical coherence 
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tomography (OCT) has been introduced as an invasive technique that provides images of 
vessel wall morphology and plaque characteristics (Prati et al., 2009; Bezerra et al., 2009).  
By using these novel techniques, an array of biomarkers assessing plaque growth and 
destabilization, myocardial stress and ischemia, along with inflammatory processes, has 
been developed, including cellular adhesion molecules, cytokines, and proatherogenic 
enzymes. Importantly, different biomarkers may look at different phases of coronary 
atherosclerotic disease and CAG, along with IVUS, angioscopy and OCT, may be of great 
clinical utility in assessing the role of these new biomarkers in coronary atherosclerosis 
pathophysiology  (Libby & Theroux, 2005; Hansson, 2005). 
The present chapter will summarize our current understanding of inflammatory and non-
inflammatory biomarkers, validated with intracoronary imaging modalities, their presumed 
pathophysiological role in coronary atherosclerosis and the clinical evidence that supports 
their prognostic importance.  
2. Soluble biomarkers  
A dynamic inflammation model has supplanted the previously held view of atherosclerosis 
as a passive deposition of debris in the arterial wall (Libby, 1995a, 1995b; 2001; 2002; Libby & 
Theroux, 2005). Numerous mediators contribute to atherogenesis, including chemokines, 
cytokines, growth factors, proteases, adhesion molecules, hemostasis regulators, and 
receptors, and their interactions may regulate plaque progression and instability (Blake & 
Ridker, 2002;).  
A biomarker is defined as a characteristic that is objectively measured and evaluated as an 
indicator  of normal biologic processes or pathogenic processes or as a physiologic response 
to a therapeutic intervention. In clinical medicine, biomarkers are routinely used in disease 
diagnosis, prognosis, ongoing clinical decision-making, and follow-up to assess effects of 
therapy. A framework for the validation of biomarkers was proposed by Boissel et al. 
(Boisell et al., 1992) and subsequently adapted by Espeland et al. (Espeland et al., 2005) in a 
discussion of the usefulness of carotid ultrasound to measure the clinical efficacy of lipid-
lowering medications. Espeland et al. (Espeland et al., 2005), in modifying the terminology 
of Boissel et al. (Boisell et al., 1992), described clinical and statistical characteristics that a 
biomarker should have to be considered a surrogate marker of efficacy in atherosclerotic 
disease. Importantly, the clinical criteria outlined for validating surrogate markers are 
efficiency, linkage, and congruence. Taken together, these data suggest that four main 
factors are related to the development of effective biomarkers (Fry, 2010): 1. Analytical 
validity: the accuracy and precision with which a particular biomarker is identified by the 
Proposed test; 2. Clinical validity: the accuracy with which a test identifies or predicts a 
patient’s clinical status; 3. Clinical utility: assessment of the risks and benefits, such as cost 
or patient outcome, resulting from the test; 4. Ethical, legal or social implications. 
Several inflammatory and non-inflammatory soluble biomarkers have been widely 
investigated during the last two decades in the setting of CAD, including both stable and 
unstable pattern of clinical presentation. On the one hand, many of these biomarkers have 
been associated with the presence of CAD; on the other hand, they have been associated 
with the presence of “vulnerable” plaque, thus with an increased risk of cardiac death and 
non-fatal AMI, eventually stressing both their diagnostic and prognostic role. In this regard, 
intracoronary imaging modalities may help to understand the pathological role exerted by 
soluble biomarkers in the pathogenesis of CAD. 
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Recent research has shown that inflammation plays a key role in CAD and other 
manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their 
effector molecules accelerate progression of the lesions, and activation of inflammation can 
elicit ACS. 
3.1 C-reactive protein 
C-reactive protein (CRP) was identified more than five decades ago as an acute-phase 
reactant that was capable of activating the complement system (Tillet & Francis, 1930; 
Abernathy & Avery, 1941). It was subsequently noted to be one of a number of acute-phase 
biomarkers, along with the erythrocyte sedimentation rate and complement, which was 
elevated in AMI (Boltax & Fischel, 1956). After the development of more sensitive, reliable, 
and readily available assays for CRP, a number of epidemiologic studies were conducted to 
assess the value of CRP in predicting cardiovascular risk (Ridker et al., 1997, 2001, 2002, 
2005a, 2005b; Danesh et al., 2004; Koenig et al., 2004; Cushman et al., 2005). In a post-mortem 
study of 302 autopsies of men and women with atherosclerosis, median CRP levels were 
higher with acute plaque rupture than in stable plaques or controls (Burke et al., 2002). The 
levels correlated with the staining intensity for CRP in macrophages and the lipid core of 
plaques, and it increased with the number of thin cap atheromas found in coronary arteries. 
Moreover, plasma CRP levels at the upper end of the reference range in apparently healthy 
men and women, in the absence of other sources of inflammation, has been previously 
correlated with increased risk of future cardiovascular events, including MI, peripheral 
vascular disease with intermittent claudication and stroke (Ridker, 2001). These data 
support the view that systemic CRP accurately reflects the number of vulnerable 
atherosclerotic plaques. Liuzzo et al. (Liuzzo et al., 1994) reported that patients with UA 
and elevated levels of CRP (>3 mg/dl) had higher rates of death, AMI and need for 
revascularization compared to patients without elevated levels. Of note, this increased risk 
may be evident as early as 14 days after presentation (Morrow et al., 1998). Importantly, 
the U.S. Centers for Disease Control and Prevention and the American Heart Association 
have both advocated the use of CRP as an adjunct to global risk prediction among those at 
intermediate risk for CAD (Pearson et al., 2003). Thus, among non-specific markers of 
inflammation, CRP is the most investigated and has widely been associated with an 
increased risk of future cardiovascular events both in primary and secondary prevention 
studies (Willerson et al., 2004; Ridker et al., 1997, 2001, 2005a, 2005b; Haverkate et al., 
1997). However, the association of CRP levels with angiographic coronary atherosclerotic 
burden is controversial, whereas its association with coronary instability has consistently 
been reported in several studies. 
More than 15 years ago, Mori et al. (Mori et al., 1995) reported that baseline CRP levels were 
associated with the severity of CAD, as determined by the Gensini score and this association 
remained significant even after adjustment for body-mass index, smoking history, 
hypertension, and total cholesterol. Subsequently, Tataru et al. (Tataru et al., 2000) found a 
correlation between CRP levels and the number of diseased vessels in patients with a 
previous history of MI. Zebrack et al. (Zebrack et al., 2002) enrolled 2.554 patients with 
angina but without AMI who underwent CAG (1.848 patients had CAD and 706 patients 
did not). CAD was quantified in 5 ways and combined for a CAD score and CRP was 
measured in all patients who were followed for up to 5 years for death or MI. Interestingly, 
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CRP correlated with the extent of CAD, but correlation coefficients were low (0.02 to 0.08). 
Of angiographic measures, the CAD score best predicted future events. CRP retained 
predictive value within each quintile of CAD score. CRP and CAD independently and 
additively contributed to the risk prediction: low CRP and lowest CAD score were 
associated with lowest risk, and high CRP and highest CAD score were associated with the 
highest risk, with a 10-fold difference between extremes (2.5% vs. 24%). In conclusion, they 
demonstrated that CRP correlated with extent of CAD, but the degree of correlation was 
low, however, both severity/extent of CAD and CRP were independent and additive 
predictors of risk. Azar et al. measured CRP levels in 98 patients with stable angina or an 
abnormal stress test who were referred for diagnostic CAG. They showed that the CRP level 
did not correlate with the extent and severity of coronary narrowing measured by 
angiography (Azar et al., 2000). In the acute setting of CAD, Niccoli et al. (Niccoli et al., 
2008)  studied 97 consecutive patients with UA undergoing CAG and CRP was measured by 
an ultrasensitive nephelometric method. Atherosclerotic disease severity and extent were 
assessed by angiography using the Bogaty score. No significant correlation was found 
between baseline CRP serum levels and angiographic measures of atherosclerotic disease 
severity and extent. In this study, the authors demonstrated that in patients with UA, CRP 
serum levels and coronary atherosclerosis are not correlated, but they were both 
independently associated with a worse outcome at 6-month follow-up. In UA patients, the 
association between atherosclerotic background and CRP may be altered by the increase in 
CRP associated with the acute phase response. On the other hand, in vitro studies suggest 
that the proatherogenic role of CRP is associated with very high levels of serum CRP (up to 
50 mg/L), much higher than that observed in patients with CAD or ACS (Devaraj et al., 
2003).  
Erren et al. (Erren et al., 1999) previously evaluated 147 patients undergoing semiquantitative 
CAG and they measured CRP, serum amyloid A (SAA), and the proinflammatory cytokine IL-
6; the active and total fractions of the anti-inflammatory cytokine transforming growth factor-
b (TGF-b); the macrophage activation marker neopterin; and the infection marker 
procalcitonin. Compared with 62 patients without either CAD or peripheral artery disease, 
57 patients with CAD but no peripheral artery disease showed greater median CRP and IL-6 
levels and a lower level of active-TGF-b. Moreover, CRP, IL-6, and neopterin levels showed 
a positive and the active TGF-b level a negative correlation with the extent of coronary 
atherosclerosis. Compared with these 57 patients with CAD alone, 15 patients with 
peripheral artery disease and CAD had higher median levels of SAA, IL-6, neopterin, and 
total TGF-b. However, these strong univariate associations of markers of inflammation and 
atherosclerosis were lost in multivariate analysis once age, sex, and HDL cholesterol or 
fibrinogen were taken into account. Taken together, these data suggest that increased 
plasma levels of CRP, SAA, IL-6, TGF-b, neopterin, and procalcitonin constitute an 
inflammatory signature of advanced atherosclerosis and are correlated with the extent of 
disease but do not provide discriminatory diagnostic power over and above established risk 
factors. Indeed, as previously mentioned, Lee et al. (Lee et al., 2006) reported on the 
associations between 3 plasma markers of low-gade inflammation, such as CRP, IL-6 and 
SAA protein and total homocysteine with CAD and death in a Canadian angiography 
cohort of 1.117 patients followed for 8.5 years. They found no significant association 
between elevated levels of these biomarkers and CAD (defined as the presence of any lesion 
with stenosis greater than 10%), but they did find significant independent associations of 
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elevated IL-6 (a key pro-inflammatory cytokine) and homocysteine levels with both CAD-
related and all-cause death. These findings do not support the hypotheses that these 
biomarkers play a causal role in atherogenesis. The importance of this study is that no 
previous studies have examined such associations in a large, prospective angiographic 
cohort in which CAD was defined using sensitive criteria. However, it is worth noting that 
when Lee et al. used the definition of CAD as the presence of any lesion of 50% stenosis 
(which was developed for assessing suitability for cardiac surgery or angioplasty), they 
observed significantly higher CRP and IL-6 levels in the CAD group (Lowe et al., 2005). 
On the other hand, several data suggest that CRP may be a marker of plaque activity 
(Liuzzo et al., 1994). In a previous report, Arroyo-Espliguero et al (Arroyo-Espliguero et al., 
2004) sought to assess whether CRP was an independent predictor of future cardiovascular 
events after adjustment for CAD severity and whether CRP levels correlate with number of 
angiographically complex coronary artery stenosis. They studied 825 consecutive anginal 
patients (700 with chronic stable angina and 125 with ACS without ST-segment elevation). 
The composite endpoint of non-fatal AMI, hospital admission with class IIIb UA and cardiac 
death was assessed at 1 year follow-up. CRP levels were higher in chronic stable angina 
patients with the combined end-point (p=0.03) after adjustment for number of diseased 
coronary arteries. CRP was also significantly higher in patients with ACS compared to 
stable patients (p=0.004) and correlated with number of complex angiographic stenoses 
(p=0.01). Interestingly, in this report, CRP levels predicted future cardiovascular events 
independently of CAD severity and correlated with number of angiographically complex 
coronary artery stenosis in patients with ACS, thus suggesting that CRP levels may be a 
marker of atheromatous plaque vulnerability and CAD activity. This concept was endorsed 
by studies showing that CRP levels correlate with cardiovascular risk in ACS patients, thus 
giving further support to the increasingly accepted hypothesis that CRP is not merely a 
marker of systemic inflammation but may also be a pathogenic mechanism in ACS (Yeh et 
al., 2001; Pasceri et al., 2000; Zwaka et al., 2001). Additionally, the relation of serum CRP 
concentrations with adverse cardiovascular events during follow-up in patients with stable 
angina also suggests that clinical “stability” does not always indicate atheromatous plaque 
stability (van der Wal et al., 1999). Geluk et al. (Geluk et al., 2008) recently evaluated the 
population based on the Prevention of Renal and Vascular Endstage Disease (PREVEND) 
study. Of note, 8.139 subjects without previous documented CAD were followed for the 
incidence of CAD and coronary events from 1997 to 2003. In the prospective PREVEND 
study of subjects without previous documented CAD, CRP levels at baseline were 
associated with angiographic characteristics and clinical consequences of plaque instability 
during follow-up. Because CRP was weakly correlated with angiographic plaque burden, it 
was suggested that CRP is stimulated not only by the extent of atherosclerosis but, 
importantly, by other factors. Indeed, they postulated that CRP is a measure of inflammed, 
unstable atherosclerotic plaque (both angiographically visible and occult), whereas 
angiography indicates the extent of visible stable and unstable occlusive plaque. The value 
of CRP in predicting future death or MI was apparent in all ranges of CAD severity. Those 
with extensive CAD were at relatively high risk of death or MI regardless of CRP levels. 
However, in the presence of a low to moderate risk angiogram (or even a normal 
angiogram), CRP became particularly useful in distinguishing patients at substantially 
lower versus higher risk for death or MI. A particularly high risk was observed in subjects 
with lower CAD scores but highly elevated CRP despite a lower prevalence of all traditional 
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risk factors in these patients with low/moderate CAD scores (i.e., lower cholesterol levels, 
absence of diabetes, hypertension). Because these patients may be considered to have 
insignificant CAD and hence to be at low risk for MI, less aggressive medical therapy may 
be offered to them in comparison to patients with more extensive CAD, thus possibly 
underestimating their cardiovascular risk (Pearson et al., 2003; Lowe, 2005; Beaglehole & 
Magnus, 2002; Greenland & O’Malley, 2005). 
With the introduction of IVUS, new important data regarding CRP levels and CAD burden 
and, especially, plaque morphology have been provided, shedding some lights on CRP 
diagnostic and prognostic role in CAD patients. Sano et al. (Sano et al., 2003) investigated 
the relation between lesion morphology as seen under pre-intervention IVUS and CRP in 90 
consecutive patients presenting with AMI. Patients were divided into an elevated CRP 
group (3 mg/L) or a normal CRP group on the basis of serum CRP levels. There were no 
differences in patient characteristics or angiographic findings. Interestingly, they observed 
significantly more plaque rupture in the elevated CRP group than in the normal CRP group 
(70% versus 43%, p=0.01). A multivariate logistic regression model revealed that the 
presence of ruptured plaque alone correlated with elevation of serum CRP (p=0.02; odds 
ratio, 3.35; 95% CI, 1.22 to 9.18). These data further suggest that in the setting of AMI, 
elevated CRP levels may reflect the inflammatory activity of a ruptured plaque. 
Additionally, Sano et al. (Sano et al., 2003) found that in the normal CRP group, 44% of 
analyzed lesions were non–rupture-type lesions. Indeed, several pathological reports 
showed that AMI may be caused not only by plaque rupture but also by plaque erosion, 
which is a major substrate for coronary thrombosis in AMI (van der Wal et al., 1994; Farb et 
al., 1996; Arbustini et al., 1999). A more recent IVUS study (Otake et al., 2008) investigated 
the relation between plasma CRP and adiponectin and coronary plaque components in 
patients with ACS. Ninety-three culprit plaques (ACS n=50, non-ACS n=43) and 56 
nonculprit plaques (ACS n=28, non-ACS n=28) were analyzed using virtual histology (VH)-
IVUS to examine relations among plasma CRP, adiponectin, and ratios of each coronary 
plaque component. Plasma adiponectin was significantly lower and plasma CRP was 
significantly higher in patients with than without ACS. Notably, culprit plaques in patients 
with ACS had greater amounts of necrotic core plaque than those in patients without ACS. 
There was an inverse relation between CRP and adiponectin with regard to necrotic core 
ratio in both culprit and nonculprit lesions in patients with ACS, but not those without ACS. 
Thus, once again, increased plasma CRP levels might be related to the progression of ACS. 
Zhang et al. (Zhang et al., 2006) performed IVUS examination in 152 patients with 
confirmed CAD before percutaneous coronary intervention and measured CRP levels in all 
patients. Unstable and ruptured plaque were found more frequently in patients with AMI 
and UA. The levels of plasma CRP were higher in ruptured plaque group. CRP >8.94 mg/L 
was used to predict ruptured plaque with a ROC curve area of 0.76 (95% confidence 
interval, 67.0%-85.8%), sensitivity of 71.8%, specificity of 77.0% and accuracy of 69.2% 
(p<0.01). Chen et al. (Chen et al., 2007) aimed at investigating whether combined IVUS and 
measurements of serum inflammatory biomarkers could predict coronary plaque ruptures 
in patients with angina pectoris. The study population consisted of 20 patients with stable 
angina and 40 patients with UA. IVUS was performed in the 2 groups to measure intima-
media thickness, the plaque acoustic density of the common carotid arteries, and the flow-
mediated dilation of the brachial arteries. Serum lipid profile and inflammatory biomarkers 
were measured in all patients. Of 139 coronary artery plaques identified by IVUS, 48 
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plaques (9 in stable angina and 39 in UA) developed ruptures. Among measured 
parameters, they found that the values of carotid intima-media thickness, coronary external 
elastic membrane area, plaque area, plaque burden, plaque eccentric index and remodeling 
index, and serum CRP were significantly higher in UA patients than in stable angina 
patients (p<0.05 to 0.01). Additionally, they found that soluble intercellular adhesion 
molecule-1, and soluble vascular cell adhesion molecule-1 were significantly higher in UA 
patients (p<0.05). However, of these parameters, carotid intima-media thickness, serum 
CRP, and the coronary remodeling index, only, were found to be significant predictors of 
coronary plaque rupture, with odds ratios of 9.51 (95% confidence interval 1.29 to 21.81), 
3.02 (95% confidence interval 1.01 to 7.65), and 0.01 (95% confidence interval 0.00 to 0.34), 
respectively. Taken together, these data suggest the intriguing possibility that the 
association between CRP and risk of cardiovascular events is mediated by unstable plaque 
phenotype, raising the possibility that CRP is not only a marker of vascular inflammation 
but also of plaque disruption. However, Park et al. (Park et al., 2010) recently enrolled 188 
patients who underwent 3-vessel VH-IVUS with peripheral blood sampling, including CRP 
levels measurements. VH-TCFA was defined as a necrotic core >10% of plaque area in the 
presence of >40% plaque burden. There were 38 patients with ruptured plaque and 150 
patients without (107 patients with VH-TCFA, 43 patients without VH-TCFA) in culprit/target 
lesions. In the present study there were no significant differences in the CRP level between 
patients with and without VH-TCFA in the culprit/target lesions. However, it is worth 
mentioning that when lesions are analyzed post-rupture, after the necrotic core may have 
embolized, they most often appear “dark-green” and will be classified as fibrotic plaque rather 
than necrotic core in VH-IVUS analysis, and have a reduced calculated relative size of the 
necrotic core. Therefore, when the relationships between each plaque characteristic and 
plasma biomarker levels, including CRP, were evaluated in the study performed by Park et al. 
(Park et al., 2010), ruptured plaques were excluded to avoid the possibility of incorrect VH-
IVUS interpretation and this may partially explain the different results between studies. 
Takano et al. (Takano et al., 2005) have evaluated, using coronary angioscopy, changes of 
ruptured plaques in non culprit lesions in living patients and ability of CRP to predict 
disease activity of the plaque ruptures, also shown in other previous studies (Ishibashi et al., 
2002). They have identified by angioscopy 48 thrombi in 50 ruptured coronary plaques in 
nonculprit lesions in 30 patients with mean angioscopic follow-up period was 13 +/- 9 
months. They have shown that ruptured plaques in nonculprit lesions tend to heal slowly 
with a progression of angiographic stenosis and the serum CRP level in patients with healed 
plaques was lower than that in those without healed plaques, although  in patients with 
healed plaques did not significantly decrease from baseline to follow-up. Of note, at 
univariate logistic regression, serum CRP levels at follow-up were predictors of healing in 
nonculprit ruptured plaques, while, a multivariate logistic regression analysis, the authors 
showed that serum CRP levels at follow-up were not independent predictors of plaque 
healing. Thus, the power of serum levels of CRP in predicting disease activity should also be 
confirmed. Furthermore, the same authors have previously reported that statin therapy 
reduces the serum CRP level and angioscopic complexity of the plaques (the existence of 
the thrombus and the irregularity of the plaque) in nonculprit lesions (Takano et al., 2003). 
In this study, data  from univariate logistic regression analyses indicated that both statin 
therapy and serum CRP level at follow-up are considered predictors of healing in 
nonculprit ruptured plaques. However, a multivariate logistic regression analysis showed 
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that neither statin therapy nor serum CRP level at follow-up is an independent predictor of 
plaque healing. These findings, however, should be confirmed in larger study populations. 
A study by Tanaka et al. (Tanaka et al., 2008) enrolled 43 consecutive ACS patients (with 
or without ST-segment elevation) undergoing OCT assessment and presenting with a 
ruptured plaque at the culprit site. Patients were divided into a rest group and an exertion 
group on the basis of their activities at the onset of ACS. Of interest, the thickness of the 
broken fibrous cap correlated positively with activity at the onset of ACS. The culprit 
plaque ruptured at the shoulder more frequently in the exertion group than in the rest 
group (rest 57% versus exertion 93%, p=0.014). The thickness of the broken fibrous cap in 
the exertion group was significantly higher than in the rest-onset group (rest onset: 50 µm 
[interquartile median 15 µm]; exertion: 90 µm [interquartile median 65 µm], p<0.01). These 
data suggest a thin-cap fibroatheroma (TCFA) is a lesion predisposed to rupture both at 
rest and during the patient’s day-to day activity, and some plaque rupture may occur in 
thick fibrous caps depending on exertion levels. Moreover, this study demonstrated also 
an inverse relationship between fibrous cap thickness and serum levels of CRP (r=-0.31, 
p<0.01). Li et al. (Li et al., 2010) investigated in stable and unstable patients the relationship 
between plaque morphology assessed by OCT and serum levels of several inflammatory 
biomarkers, such as CRP, IL-18, TNF-α, white blood cell count.  This study demonstrated 
that the plasma levels of inflammatory factors and white blood cell count were correlated 
inversely with fibrous cap thickness (r=0.775 for CRP, r=-0.593 for IL-18, r=-0.60 for TNF-α, 
and r=-0.356 for white blood cell count). Patients with TCFA (cap thickness less than 65 
micron) had higher plasma levels of inflammatory factors as well as WBC counts than those 
with thicker fibrous caps. ROC curves for CRP, IL-18, TNF-α and white blood cell count, 
which displayed the capability of prediction about TCFA, showed the area under the curves 
were 0.95, 0.86, 0.79 and 0.70 (p<0.05), respectively. Meanwhile, in multivariate logistic 
regression analysis, CRP was the only significant independent predictor of TCFA. Therefore, 
although IL-18, TNF-α and white blood cell count could also show similar characteristics, 
their predictive value was weak compared with CRP. 
Kashiwagi et al. (Kashiwagi et al., 2009) evaluated the relationship between coronary 
arterial remodelling assessed by IVUS, fibrous cap thickness assessed by OCT and CRP 
concentrations in patients with ACS. Positive remodelling was defined as 
remodelling>1.05, intermediate remodelling as remodelling=0.95–1.05, and negative 
remodelling as remodelling<0.95. On the basis of the IVUS findings, patients were 
divided into 2 groups (positive remodelling group, intermediate remodelling/negative 
remodelling group). Lipid-rich plaques and TCFA were more frequent in the positive 
remodelling group than in the other group and intermediate remodelling inversely 
correlated with the thickness of fibrous cap. Levels of CRP were higher in the positive 
remodelling group than in the other group and were higher in patients with a thin fibrous 
cap, suggesting that the inflammatory process may simultaneously contribute to both 
plaque growth and plaque instability.  
Kitabata et al. (Kitabata et al., 2010) investigated in stable and ACS patients the relationship 
between the presence of microchannels in coronary plaque  assessed by OCT and serum 
CRP levels. Microchannel was defined as a no-signal tubuloluminal structure on the cross-
sectional OCT image. Microchannels were found in 24 (38%) of the 63 enrolled patients and 
patients were divided into 2 groups according to the presence or absence of microchannels. 
The frequency of plaque rupture tended to be greater in the microchannel group (50% vs 
www.intechopen.com
Biomarkers and Coronary Atherosclerotic Burden and Activity as 
Assessed by Coronary Angiography and Intra-Coronary Imaging Modalities 
 
383 
28%, p=0.11). The thickness of the fibrous cap (median 60 vs 100 micron, p=0.001) was 
significantly lower in the patients with microchannels, and significant differences were 
found in the frequency of thin-cap fibroatheroma (54% vs 21%, p=0.012) and positive 
remodeling (67% vs 36%, p=0.02) between the 2 groups. CRP levels in the microchannel 
group were significantly greater than those in the no-microchannel group (median 0.27 vs 
0.13 mg/dl, p=0.015). Moreover, increased microchannel counts were associated with 
greater high-sensitivity CRP levels (p=0.01). Takarada et al. (Takarada et al., 2010) enrolled 
82 Non-ST-elevation-ACS patients undergoing OCT assessment of culprit lesion at baseline 
and after 9 months, evaluating morphological changes of coronary plaque and changes in 
serum levels of CRP. Of interest, the change in fibrous cap thickness had a significant 
positive correlation with changes in CRP levels (r=0.44, p<0.01). A recently published study 
by Ferrante et al. (Ferrante et al., 2010) enrolled 25 consecutive ACS patients undergoing 
percutaneous coronary intervention and OCT assessment, evaluating the relationship 
between plaque morphology and serum levels of myeloperoxidase (MPO) and CRP. OCT 
classified the culprit lesion as ruptured in 18 (72%) or eroded in 7 patients (28%) and 
detected intraluminal thrombus in 89% of ruptured plaques and 100% of eroded plaques. 
CRP levels did not differ significantly between patients with an eroded plaque and those 
with a ruptured plaque (median, 11.3 mg/L; 25th to 75th percentile, 1.3 to 28.5 versus 
median, 3.9 mg/L; 25th to 75th percentile, 1.3 to 17.8; p=0.76, respectively). On the contrary, 
a study by Bouki et al. (Bouki et al., 2010)  showed that higher levels of serum CRP and IL-18 
were found in patients with plaque rupture vs. those with no plaque rupture (median value: 
19.2mg/L vs. 1.6mg/L, p<0.001 and 219.5pg/ml versus 127.5pg/ml, p=0.001 respectively), 
and TCFA versus those without TCFA (median value: 15.2mg/L versus 1.6mg/L, p=0.004 
and 209.0pg/ml versus 153.2pg/ml, p=0.03, respectively). Moreover, serum CRP was the 
only independent predictor of plaque rupture (p=0.02, odds ratio 1.1, 95% confidence 
interval 1.0 to 1.2), and a cut-off value of CRP>4.5mg/L could detect ruptured plaque with a 
sensitivity of 91.7% and a specificity of 77.8%. Taken together, these data show that the 
association of CRP levels with coronary atherosclerotic burden is still controversial, whereas 
its association with coronary instability has consistently been reported in several studies, by 
using different intracoronary imaging modalities. Although initially considered only a 
marker of inflammation, CRP itself has been shown to possess proinflammatory and pro-
atherogenic properties. It stimulates endothelial cells to express adhesion molecules and 
secrete cytokines (Pasceri et al., 2000, 2001) and it decreases the expression of endothelial 
nitric oxide synthase (Verma et al., 2002; Venugopal et al, 2002). CRP accumulates in 
macrophage-rich regions of nascent atherosclerotic lesions and activates the macrophages to 
express cytokines and tissue factor, while enhancing macrophage uptake of LDL (Zwaka et 
al., 2001). It also amplifies pro-inflammatory effects of several other mediators including 
endotoxin (Nakogomi et al., 2000; Burke et al., 2002). These biological properties exerted by 
CRP may be held responsible for the detrimental role of this acute-phase reactant which 
may participate in the unstable patter of CAD. 
To date, there are no widely accepted and established markers of inflammation for 
cardiovascular disease and no known therapeutic measures to modulate coronary 
inflammation. CRP is currently the best marker of inflammation, and in addition to weight 
loss, exercise, and smoking cessation, statins are the best therapeutic option to modulate 
inflammation. New avenues for diagnosing and treating coronary inflammation should be 
investigated in larger and randomized trials. 
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With improved understanding of the critical role of inflammation in atherothrombosis, 
attention has been focused on the circulating markers of inflammation, including fibrinogen 
(Ross, 1993; 1999; Lind, 2003). Evidence has been accumulated from several prospective 
studies that showed that high levels of fibrinogen were associated with an increased risk of 
coronary, cerebral and peripheral disease (Maresca et al., 1999; Danesh et al., 2004; Tamam 
et al., 2005). In a prospective study, Espinola-Klein et al. (Espinola-Klein et al. 2007) enrolled 
720 patients preceding CAG. Patients were compared with regard to atherosclerotic burden 
and classified as follows: no clinically significant stenosis (n=57, 7.9%), CAD only (n=362, 
50.3%), CAD with peripheral atherosclerosis (=multi-vascular atherosclerosis, n=301, 41.8%). 
They found a significant association between elevation of CRP and atherosclerotic burden 
(control: 2.6 (1.4–6.8) mg/l; CAD: 4.5 (2.1–12.1) mg/l; multi-vascular: 5.2 (2.0–15.6) mg/l, 
p<0.001). Results were similar with regard to IL-6 according to the extent of atherosclerosis 
(control: 7.8 (4.0–13.2) ng/ml; CAD: 11.4 (5.2–22.8) ng/ml; multi-vascular: 12.5 (5.8–
24.5) ng/ml, p<0.001). The strongest association was registered, indeed, between elevation 
of fibrinogen and extent of atherosclerosis (control: 296.0 (256.0–326.5) mg/dl; CAD: 329.0 
(281.8–399.3) mg/dl; multi-vascular: 351.0 (289.5–434.5) mg/dl, p<0.0001). Additionally, 
follow-up data after a median of 6.5 years were available in 719 patients (99.9%), and 75 
patients (10.4%) died from cardiovascular causes. Presence of multi-vascular atherosclerosis, 
elevation of IL-18 and elevation of fibrinogen were independently related to cardiovascular 
death in a fully adjusted model Hazard ratio (95% confidence interval) 2.0 (1.2-3.5) for 
presence of multi-vascular atherosclerosis (p<0.01), 2.2 (1.2-3.9) for high fibrinogen (p<0.01) 
and 2.8 (1.6-4.9) for high IL-18 (p<0.0001). Fibrinogen was achieved as independent 
predictor for both, mortality and atherosclerotic burden, whereas IL-18 was not related to 
atherosclerotic burden. These data suggest that fibrinogen was the only inflammatory 
marker with an independent association to the extent of atherosclerosis in the arterial vessel 
three. Previous investigations found also a strong interdependence between high serum 
fibrinogen levels and severe peripheral occlusive disease, indicating advanced 
atherosclerosis (Wattanakit et al., 2005). Presumably, the predictive value of high fibrinogen 
level is caused by the association to high atherosclerotic burden which is predictive for a 
worse prognosis itself.  Concordantly, Hoffmeister et al. (Hoffmeister et al., 2001) previously 
conducted a case-control study to assess the association between various markers of 
inflammation and the presence and severity of chronic stable CAD. They included 312 
clinically stable patients with angiographically documented CAD, and the severity of CAD 
was evaluated by 3 coronary scoring systems: the clinical 1- to 3-vessel disease score, the 
American Heart Association extension score (1 to 15 segments), and the Gensini score. 
Fibrinogen levels were highly significantly elevated (p<0.005) in patients with stable CAD 
compared with controls. After multivariable adjustment by means of logistic regression 
analysis, the association between CAD and fibrinogen remained substantial. However, no 
association between fibrinogen levels and any of the coronary scores applied was found. 
Finally, Memon et al. (Memon et al., 2006) measured plasma fibrinogen levels in 138 patients 
with angiographically assessed CAD and in 183 healthy subjects matched according to age 
and gender. According to the number of significantly stenosed (>or=50%) vessels, the 
patients were classified in four groups: those without stenosis (0-vessel disease) and those 
with 1, 2 or 3-vessel disease. Fibrinogen levels were significantly higher in patients than in 
controls (p<0.001). Although fibrinogen levels tended to increase with the number of 
stenotic vessels, the differences were not statistical significant.  
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Taken together these data suggest that fibrinogen can be discussed as a serological marker 
of high atherosclerotic burden within arterial vessel tree and may be a screening marker to 
identify patients that should be evaluated carefully for atherosclerotic manifestations. 
3.3 Eosinophil cationic protein 
Leukocyte recruitment and expression of proinflammatory cytokines characterize all steps 
of atherothrombosis (Libby & Theroux, 2005). Recent observations suggest that eosinophils 
may play a role in coronary atherosclerosis. Indeed, prospective studies have consistently 
shown an association between eosinophil count and increased risk for future cardiovascular 
events (Prentice  et al., 1982; Lee et al., 2001). Furthermore, eotaxin, an eosinophil-specific 
chemoattractant, is overexpressed in human atherosclerotic lesions (Haley et al., 2000) and 
patients with CAD show higher circulating levels of eotaxin as compared to healthy controls 
(Economou et al., 2001; Emanuele et al., 2006). Accordingly, a nonconservative 
polymorphism in the eotaxin gene (Zee et al., 2004) together with sequence variants 
affecting eosinophil count (Gudbjartsson et al., 2009) have recently been associated with an 
increased risk of myocardial infarction. Eosinophil cationic protein (ECP) is a zinc-
containing, highly cationic protein, stored in the peroxidase-positive and negative 
eosinophil granules which is secreted through priming by various triggers, such as 
immunoglobulins and complement components (Venge et al., 1999). Several studies have 
shown that the measurement of ECP in most biological fluids may be used as a marker of 
eosinophil activity and turnover, and that increased ECP serum levels are related to the 
presence, activity and severity of asthma, atopic disorders, and other immune diseases, such 
as rheumatoid arthritis, psoriasis, and adult celiac disease (Hällgren et al., 1991). In this 
regard, the role of ECP in CAD has been recently assessed (Niccoli et al., 2010). One-
hundred and ninety-eight consecutive anginal patients with angiographic evidence of CAD 
(stable angina or non-ST-elevation-ACS), or with angiographically normal coronary arteries 
were enrolled. The severity of CAD was graded according to Bogaty’s score and coronary 
lesion morphology was defined as smooth or complex. Baseline ECP and high sensitivity 
CRP were measured in all patients. ECP levels were significantly higher in stable angina 
patients (p<0.001) and non-ST elevation-ACS (p=0.016) compared to patients with normal 
coronary arteries, without significant difference between stable and unstable patients 
(p=0.45). Additionally, CRP levels were significantly higher in unstable patients compared 
to stable patients (p=0.03) and normal coronary arteries patients (p<0.001), without 
significant difference between stable and normal coronary arteries patients (p=0.20). The 
addition of ECP to main cardiovascular risk factors improved the area under the curve from 
0.88 to 0.92, p=0.007 for the angiographic diagnosis of CAD; further addition of CRP 
increased the area to 0.94, p=0.014. At multiple linear regression analysis, ECP levels 
independently predicted CAD severity (p=0.001), whereas CRP levels independently 
predicted lesion complexity (p=0.01). Taken together, these data suggest that ECP is a 
marker of CAD and that different inflammatory biomarkers reflect different phases of 
atherosclerotic plaque evolution (Niccoli et al., 2010). Further studies should address the 
role of ECP in CAD on larger study populations. 
3.4 Myeloperoxidase  
MPO is a member of the peroxidise superfamily that is predominantly found in neutrophils, 
monocytes and tissue macrophages and is released upon their activation as a response to 
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various stimuli (Nicholls et al., 2005). The enzyme is part of an innate host defence that acts 
on its substrate hydrogen peroxide of various sources augmenting its oxidative potential by 
producing potent oxidative species capable of modifying various cellular components by 
chlorination, nitration and cross-linking (Podrez et al., 2000; Heinecke et al., 2003). 
Demonstrations that MPO and its oxidation products are enriched within human atheroma 
(Daugherty et al., 2004) has increased interest in this enzyme in directions such as its 
participation in the promotion of atherosclerosis (Hazen et al., 1997), destabilization of 
atherosclerotic plaque (Sugiyama et al., 2001, 2004; Naruko et al., 2002) and in the possibility 
that MPO can serve as a biomarker to predict future adverse events in patients with CAD 
(Baldus et al., 2003; Brennan et al., 2003). Clinical studies have shown that plasma levels of 
MPO are increased in patients with stable CAD (Zhang et al., 2001) , ACS (Baldus et al., 
2003; Brennan et al., 2003), and ST-segment elevation AMI (Mocatta et al., 2007; Khan et al., 
2007). Other studies have proven that neutrophils, the main source of MPO release, are 
activated in ACS; however, their activation has not been linked with ischaemia/reperfusion 
per se (Biasucci et al., 1996). Furthermore, some observational studies have shown that 
baseline MPO plasma levels are predictive of future adverse coronary events in patients 
with acute chest pain (Brennan et al., 2003) or ACS (Baldus et al., 2003; Cavusoglu et al., 
2007) regardless of troponin levels.  
Ndrepepa et al. (Ndrepepa et al., 2008) recently conducted a case–control study in which 874 
patients with angiographically proven CAD were included. Cases included 680 patients 
with CAD (382 patients with stable CAD, 107 patients with non-ST-segment elevation-ACS 
and 191 patients with ST-segment elevation AMI), while controls included 194 subjects with 
normal coronary angiograms. MPO was measured using an enzyme immunoassay before 
angiography and heparin administration. MPO levels were significantly higher in cases as 
compared to controls (p<0.001). MPO levels were significantly higher in patients with AMI 
as compared to patients with stable CAD and with non-ST-segment elevation-ACS 
(p<0.0001). Elevated MPO level was associated with ACS with an area under receiver 
operating characteristic curve of 0.731 (95% confidence interval 0.692–0.770; p<0.001). 
Independent correlates of MPO level were ACS (p<0.001), CRP (p=0.007), creatinine 
(p=0.026), left ventricular ejection fraction (p=0.027, negative association) and smoking 
(p=0.028). Taken together, these data suggest that MPO level is elevated in patients with 
CAD and higher levels of MPO may be found with progression of CAD from stable CAD to 
non-ST-segment elevation ACS and to AMI. In a recent study, Wainstein et al. (Wainstein et 
al., 2010) have demonstrated that, in stable CAD, there was no association between MPO 
polymorphism and CAD severity, although a relationship was observed between plasma 
MPO levels and extent of CAD. de Azevedo et al. (de Azevedo et al., 2011) recently tested 
the hypothesis that MPO levels are higher in ACS patients with a greater extent of 
angiographic coronary involvement, by performing a cross-sectional study, examining high 
risk ACS patients who underwent CAG within 72 hours of the onset of symptoms and 
measuring their plasma MPO levels after sheath insertion. Gensini score was used to 
evaluate angiographic severity of CAD in 48 patients. Spearman’s correlation coefficient did 
not show a significant association between MPO levels and Gensini scores (r=0.2; p=0.177). 
There was no correlation between MPO and age, hypertension, diabetes, leukocyte count, 
troponin I, CK-MB, TIMI risk score C4 and Gensini score in the multivariate analysis. These 
findings indicate that MPO expression may not be associated with anatomical severity of 
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coronary lesions in ACS. However, in a previous study (Düzgünçinar et al., 2008), 48 stable 
CAD patients with angiographically documented coronary lesions were enrolled and the 
authors demonstrated a weak, but statistically significant association between MPO levels 
and Gensini score (r=0.228; p=0.04). Of note, they found a stronger association between 
MPO levels and calcium scores by multislice computed tomography in 30 patients (p=0.02). 
In another study, MPO levels were considered independent predictors of multivessel 
disease in 389 unselected stable and unstable patients referred for CAG (Cavusoglu et al., 
2006). On the other hand, Kubala et al. (Kubala et al., 2008) evaluated 557 clinically stable 
patients submitted to CAG and did not find a significant difference in MPO levels between 
patients with documented CAD (at least 1 vessel with 50% stenosis) and patients without 
CAD. Finally, in a recently published cross-sectional study, after evaluating 118 stable CAD 
patients, a lack of association between MPO promoter polymorphism and angiographic 
severity of coronary atherosclerosis was observed (Wainstein et al., 2010). Nevertheless, as a 
secondary objective, that study revealed a trend toward greater angiographic severity of 
CAD among patients with plasma MPO levels in the upper range (Wainstein et al., 2010). 
The lack of association might be attributed to the fact that angiography-based Gensini scores 
provide information on anatomical severity, hindering a functional and morphological 
analysis of the atherosclerotic plaque. A recently published study by Ferrante et al. (Ferrante 
et al., 2010) enrolled 25 consecutive ACS patients undergoing PCI and OCT assessment, 
evaluating the relationship between plaque morphology and serum levels of 
myeloperoxidase (MPO) and CRP. OCT classified the culprit lesion as ruptured in 18 (72%) 
or eroded in 7 patients (28%) and detected intraluminal thrombus in 89% of ruptured 
plaques and 100% of eroded plaques. Baseline systemic levels of serum MPO were 
significantly higher in patients with an eroded plaque than in those with a ruptured plaque 
(median, 2500 ng/mL; 25th to 75th percentile, 1415 to 2920 versus median, 707 ng/mL; 25th 
to 75th percentile, 312 to 943; p=0.001), whereas CRP levels did not differ significantly 
(median, 11.3 mg/L; 25th to 75th percentile, 1.3 to 28.5 versus median, 3.9 mg/L; 25th to 
75th percentile, 1.3 to 17.8; p=0.76, respectively). In addition, the same study  showed that 
the density of MPO-positive cells within thrombi overlying plaques in postmortem coronary 
specimens retrieved from sudden coronary death victims was significantly higher in lesions 
with erosion (n=11) than ruptures (n=11) (median, 1584; 25th to 75th percentile, 1088 to 2135 
cells/mm2 versus median, 579; 25th to 75th percentile, 442 to 760 cells/mm2; p=0.0012). Of 
importance, this study supports the concept that elevations in specific inflammatory 
biomarkers reflect different morphologies of complications of coronary atherosclerosis and 
highlights the heterogeneity of coronary mechanisms of ACS.  
Taken together, these data suggest a controversial role of MPO for CAD burden, while an 
involvement in disease activity seems to be clear. However, this issue should be investigated 
in larger studies and, again, IVUS and OCT may play a crucial role in the accurate 
assessment of plaque vulnerability. 
3.5 Matrix metalloproteinases 
In human atherosclerosis, unstable atherosclerotic plaque is an important event that 
triggers ACS. Plaque rupture frequently correlates with loss of the extracellular matrix at 
certain locations, often in the shoulder areas of the plaque. Focal destruction of the 
extracellular matrix renders the plaque less resistant to mechanical stresses imposed 
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during systole and therefore vulnerable to rupture. Recent findings have revealed 
enhanced expression of matrix metalloproteinases (MMPs) in the vulnerable region of 
plaques and this contributes to the weakening of plaque caps by degrading the 
extracellular matrix. 
MMPs are a family of zinc-containing endoproteinases that share structural domains but 
differ in substrate specificity, cellular sources, and inducibility. The list of MMPs has grown 
rapidly in the past several years, and by now >20 mammalian members have been cloned 
and identified. The members of the MMP family can degrade all of the components of the 
blood vessel wall and therefore play a major role in both physiologic and pathologic events 
that involve the degradation of extracellular matrix components. 
In recent studies using knockout mice, electrical injury of femoral arteries in mice which 
stimulates intimal thickening, caused enhanced expression of MMP-2 and MMP-9 (Lijnen et 
al., 1998). In TIMP-1-deficient mice intimal thickening was significantly higher compared 
with that in wild-type controls (Lijnen et al., 1999) Together, these observations support a 
role for MMP involvement in intimal thickening, particularly in migration of vascular 
smooth muscle cells. Previous studies demonstrated that lipid-laden macrophages from 
human atherosclerotic plaque elaborate MMP-1 and MMP-3 (Galis et al., 1995) and culture 
of macrophages with fibrous caps of human atherosclerotic plaque induces MMP-
dependent collagen breakdown (Shah et al., 1995). Other researchers have also detected the 
expression of several other MMPs including MMP-1, MMP-2, MMP-7, MMP-9, and MMP-12 
in the shoulder areas of plaque (Shu et al., 1998). Brown et al. (Brown et al., 1995) reported 
that MMP-9 was commonly expressed in coronary atherectomy specimens from patients 
with recent plaque rupture. Kai et al. (Kai et al., 1998) reported that circulating MMP-2 and 
MMP-9 levels on admission were elevated in patients with AMI and UA. Inokubo et al. 
(Inokubo et al., 2001) also reported that plasma levels of MMP-9 were significantly increased 
in the coronary circulation in patients with AMI and UA compared with those in control 
subjects, suggesting a process of active plaque rupture in ACS. Hirohata et al. (Hirohata et 
al., 1997) also observed increased plasma MMP-1 and MMP-2 levels, respectively, in 
patients with AMI. Thus, increased MMP expression may modulate vascular and 
ventricular remodeling in ACS. 
Wang et al. (Wang et al., 2008) evaluated the vulnerability of coronary artery plaque with 
CAG, IVUS and the levels of plasma inflammatory markers in 58 consecutive patients with 
lesion of a single blood vessel demonstrated by CAG. Patients were randomly divided into 3 
groups based on the angiographic morphology of the lesions: type I lesion group (n=16), 
type II lesion group (n=25), type III lesion group (n=17). A control group of stable angina 
(n=17) was established. A subgroup of 28 patients (including 18 ACS patients and 10 stable 
angina control patients) who underwent IVUS study were analyzed. Then the plasma levels 
of MMP, including MMP-2 and MMP-9, CD40L and PAPP-A were measured with ELISA, 
along with CRP levels. The plasma levels of MMP-2, MMP-9 and PAPP-A in type II lesion 
group were significantly higher than the other groups (p< 0.05, 0.05, 0.001, respectively). In 
type II lesion group, linear correlation analysis manifested significantly positive correlation 
between levels of CRP and MMP-2 (r=0.508); MMP-2 and MMP-9, CD40L, PAPP-A (r=0.647, 
0.704, 0.751, respectively); MMP-9 and CD40L, PAPP-A (r=0.491, 0.639, respectively); CD40L 
and PAPP-A (r=0.896). IVUS subgroup analysis showed that the area of plaques and 
plaques burden in culprit lesion, the incidence of high-risk plaques, remodeling index and 
positive remodeling percentage in ACS patients were significantly greater than those in the 
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control group (p=0.0001, 0.037, 0.028, 0.015, 0.040, respectively). Compared with the control 
group, the plasma levels of CRP, MMP-2, MMP-9 and PAPP-A were markedly elevated 
(p=0.033, 0.0001, 0.0001, 0.027, respectively). 
Park et al. (Park et al., 2010) recently enrolled 188 patients who underwent 3-vessel VH-
IVUS with peripheral blood sampling, including plasma levels of MMP-2,-9, tissue inhibitor 
of metalloproteinase-1, adiponectin, macrophage migration inhibitory factor, along with 
CRP levels measurements. Among the biomarkers, only the MMP-9 level was significantly 
higher in patients with ruptured plaque (p=0.002). In the subgroup without ruptured 
plaque, significant differences in the levels of several biomarkers were not observed 
between patients with and without VH-TCFA. In both culprit/target and nonculprit/non-
target vessels, the MMP-9 level showed a weak correlation with the total number of 
ruptured plaques (r=0.231, p=0.002). Among the biomarkers tested in this study, the MMP-9 
level was significantly higher in patients with ruptured plaque. However, measurement of 
several biomarkers, including MMP-9, was incapable of predicting the presence of VH-
TCFA. This 3-vessel VH-IVUS study of 188 patients showed that the plasma level of MMP-9 
might increase in patients with multiple ruptured plaques, as well as in patients with 
ruptured plaque in the culprit/target lesions. Both acute coronary syndrome and the MMP-
9 level were independent predictors of ruptured plaque in the culprit/target lesions. 
However, the presence of VH-TCFA in the culprit/target lesions or multiple VH-TCFAs 
detected by 3-vessel VH-IVUS study were not be predictive with the use of several 
biomarker assays, including MMP-9, in this study. The clinical presentation of ACS, not the 
level of the biomarkers, was the only independent predictor of VH-TCFA in the 
culprit/target lesions. MMPs belong to a family of multidomain zinc-dependent 
endopeptidases that promote degradation of all protein and  proteoglycan–core-protein 
components of the extracellular matrix (Galis et al., 2002). Among the family of MMPs, 
MMP-2 and MMP-9 are found in the macrophages and smooth muscle cells covering the 
shoulder region of atherosclerotic plaque (Galis et al., 1994). MMP-9 and MMP-2 are highly 
expressed in the vulnerable regions of atherosclerotic plaque and it has been suggested that 
they are causally involved in plaque rupture (Lijnen et al., 2003). Other studies have shown 
that the level of MMP-2 activity is higher in stable lesions of carotid artery plaque (Sluijter et 
al., 2006) and that the level of MMP-9 is increased in more unstable plaque (Sluijter et al., 
2006, Lotus et al., 2000). Blakenberg and collegues reported that a higher level of plasma 
MMP-9 was a predictor of cardiovascular mortality: the patients in the highest quartile of 
MMP-9 level (>72 ng/ml) had the highest probability of cardiovascular death (Blankenberg 
et al., 2003). Taken together, these data suggest that MMP-9 has a more significant role in 
plaque vulnerability than MMP-2, but more clinical studies are required to evaluate the 
exact role of MMP-2 in plaque vulnerability. Thus, CAG and IVUS combined with the study 
on plasma levels of inflammation mediators were helpful in judging the vulnerability of 
coronary artery plaques.  
Matrix metalloproteinases play a crucial role in initiating ACS by degrading extracellular 
matrix components, which leads to vulnerability of the plaque as well as formation of 
atherosclerotic lesions. Although the use of MMP inhibitors may have unforeseen adverse 
effects if used in the wrong setting, development of therapeutic drugs specifically targeted 








Inflammation, neovascularisation, imbalance between coagulation and anticoagulation 
system are interesting aspects (Ross  et al.,1993; Katagiri et al., 2007; Glass  et al., 2001), but 
another one is that of lipid system and coronary plaque.  
4.1 Lipid profile 
One of the major predisposing factors to atherosclerosis is an abnormal lipoprotein 
metabolism and it may be present in over 70% of patients with premature CAD (Genest et 
al., 2005).  
The association between CAD and levels of total cholesterol, LDL and low HDL has been 
proven and widely accepted in diagnostic practice. As a consequence the National 
Cholesterol Education Program III (NCEP III) recommended the analysis of Tc in 
combination with LDL and HDL-c as a basis for the screening and treatment of patients with 
CAD. High concentration of LDL cholesterol and lipoprotein (a) or low levels of HDL 
cholesterol are able to promote atheroma formation and are recognised as particularly 
important risk factors for atherosclerosis and CAD (Rosenson, 1996; . Grundy et al., 1989; 
LaRosa et al., 1990; v et al., 1994). Of note, randomised trials showed that LDL reduction 
decreases mortality and coronary events both in a primary and in a secondary prevention 
(Shepherd et al., 1995, Sacks et al., 1996). It was found that the reduction in non-fatal MI and 
CAD death was strongly correlated with the small incremented serum HDL-cholesterol 
level (Robins et al., 2001). An independent association of triglycerides (TG) with 
atherosclerosis and/or CAD remains uncertain. Some studies suggest that TG level does not 
influence the CAD risk whereas others provide some proofs that it does (Avins & Neuhaus, 
2000). Ten years ago it was suggested that there is an inverse association between HDL level 
and the number of diseased coronary vessels (Romm et al., 1991). However, some other 
studies manifested that there is no association of CAD severity with lipid concentration 
(Lekakis et al., 2000; Cerne et al., 2000). This conflicting data persuaded Tarchalski et al.  
(Tarchalski et al., 2003) to perform a prospective study for evaluation of the relationship 
between serum lipid levels and the extent of atherosclerosis within coronary arteries in 
patients with suspected CAD and no previous MI, and who were not treated with lipids 
lowering therapy before entering the study. The study was conducted in 141 patients (53.6 ± 
7.8 years old; 32 female) who underwent a routine CAG for CAD diagnosis. A modified 
angiographic Gensini Score was used to reflect the extent of coronary atherosclerosis. 
Fasting serum lipid concentrations were determined using cholesterol esterase/peroxidase 
(CHOD/PAP) enzymatic method for total cholesterol and its fractions and lipase glycerol 
kinase (GPO/PAP) enzymatic method TG evaluation. Gensini score was positively 
correlated with total cholesterol (r=0.404; p<0.001), LDL cholesterol (r=0.484; p<0.001) and 
TG (r=0.235; p=0.005). There was a negative correlation between Gensini Score and HDL 
cholesterol (r=–0.396; p<0.001). This study clearly showed that in angina pectoris patients 
with no previous MI, the extent of coronary atherosclerosis is positively correlated with pro-
atherogenic lipids, i.e. total cholesterol, LDL cholesterol and TG and negatively correlated 
with antiatherogenic HDL cholesterol. Cabin and Roberts (Cabin & Roberts, 1982) 
previously assessed the amount of cross-sectional area narrowing by atherosclerotic plaques 
histologically in each 5 mm segment of the entire lengths of the right, left main, left anterior 
descending, and left circumflex coronary arteries in 40 patients with fatal CAD and known 
fasting serum total cholesterol and TG levels. The number of 5 mm segments of coronary 
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artery narrowed severely (76 to 100% in cross-sectional area) by atherosclerotic plaques in 
each group was as follows: 172 of 505 (34%) 5 mm segments from group I; 242 of 353 (69%) 
segments from group II; 120 of 295 (41%) from group III and 425 of 884 (48%) segments from 
group IV. The mean percentage of 5 mm segments narrowed severely was significantly 
greater in group II than in group I (p<0.005) or group III (p<0.01). Additionally, the mean 
number of four coronary arteries per subject severely narrowed and the number of subjects 
with severe narrowing of the left main coronary artery were significantly greater in groups 
II and III than in group I. The percentages of 5 mm segments narrowed severely correlated 
significantly with the serum triglyceride level (p<0.03). Although it correlated with the 
number of severely narrowed coronary arteries per subject, the serum total cholesterol level, 
however, did not correlate with the percentage of 5 mm segments of coronary artery with 
severe narrowing. In 1994, Ladeia et al. (Ladeia et al., 1994) correlated lipid profile with 
CAD. One hundred patients with symptoms of CAD were studied by CAG. Coronary artery 
stenotic and normal proximal lumen were measured with a pachymeter, and the percent 
degree of obstruction calculated. CAD was documented in 74 patients, (56-75.6% men), with 
> or = 50% stenosis in 67 (90.5%), 54 (79.1%) men. The lesions were univessel in 24 (33.4%), 
bivessel in 29 (39.7%), and trivessel in 20 (27.4%). Seventy patients had total cholesterol > or 
=200 mg/dl, 29 (41.4%) > or =240 mg/dl); 69 (71.9%) LDL > or =130 mg/dl, 37 (38.5%) > or 
=160 mg/dl; 35 (36.5%) HDL <35 mg/dl and 10 TG > or =200 mg/dl. CAD patients had 
lower HDL values (38.8 +/- 10 mg/dl vs 48.2 +/- 13.6 mg/dl, p=0.01) and higher Castelli 
risk indexes (total cholesterol/HDL =5.9 +/- 1.7 vs 5.1 +/- 1.4 and LDL/HDL =4.1 +/- 1.5 vs 
3.4 +/- 1.2, p=0.04). Patients with > or =50% stenosis and multivessel disease showed higher 
Castelli risk indexes (p=0.01 and p=0.04 for total cholesterol/HDL, and p=0.01 and p=0.02 
for LDL/HDL, respectively). Twenty one (70%) of the 30 patients with total cholesterol<200 
mg/dl had CAD (28% of the patients with CAD), in whom there was a high frequency of 
patients with a low HDL level (11/21, 52.4% vs 3/9, 33%, p=0.06). Thus, lower HDL and 
higher Castelli risk indexes values were associated with more severe and intensive CAD. 
Additionally, total cholesterol <200 mg/dl is compatible with CAD, especially if there is a 
low HDL level. These findings further strengthen the need of HDL measurement for CAD 
risk assessment. 
Several mechanisms may explain these associations. The observed positive association of the 
extent of coronary atherosclerosis with total cholesterol seems to be caused by cholesterol 
present in LDL particles. Circulating LDL can enter cells via apo B/E receptors or through 
an unregulated scavenger receptor (Brown & Goldstein, 1986). The latest mechanism, 
present in smooth muscle cells and macrophages, can result in excess accumulation of 
intracellular cholesterol and the formation of foam cells. The unregulated scavenger 
receptors are able to uptake both native and modified LDL particles. The most common 
form of LDL modification is its oxidation, which can occur in any of the cells within the 
artery, including the endothelial cells, T lymphocytes, smooth muscle cells and 
macrophages (Hiltunen et al., 1998; Kloiche et al., 2000). Foam cells can rupture leading to 
the release of oxidized LDL, proteolytic enzymes and toxic oxygen derivatives that can 
altogether damage the vessel wall (Hiltunen et al., 1998; Kloiche et al., 2000, Dimmeler et al., 
1997). Oxidized (Oxy) LDL particles can promote atherosclerotic changes by several 
mechanisms, such as acting as a monocyte chemoattractant, inducing endothelial cells 
dysfunction and apoptosis, and reducing nitric oxide release and endothelium-dependent 
vasodilatation (Li & Mehta, 2000; Mathew et al., 1997; Anderson et al., 1996). Oxy LDL may 
increase platelet aggregation and thromboxane release what causes vasoconstriction and 
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thrombus formation (Chen et al., 1996). Cytokines released from activated platelets and 
injured endothelial cells can stimulate smooth muscle proliferation and the formation of 
atherosclerotic plaque (Ross, 1993). Thus, the increased LDL cholesterol is related to the 
development of atherosclerotic changes within arteries. The inverse association of Gensini 
score with HDL cholesterol observed in the study performed by Tarchalski et al. (Tarchalski 
et al., 2003) can be explained by antiatherogenic properties of HDL particles. HDL is 
engaged in reverse cholesterol transport from cells and atherosclerotic plaques into the liver 
or to other tissues (Tall, 1990). The uptake of cellular cholesterol by HDL is controlled by 
apolipoprotein A-I and cholesterol efflux regulatory protein. Apolipoprotein A-I serves as a 
signal transduction protein to mobilize cholesterol esters from intracellular pools and also 
activates lecithin-cholesterol acyltransferase dependent cholesterol esterification. 
Cholesterol efflux regulatory protein promotes the transfer of intracellular cholesterol to the 
cell membrane and surface (Marcil et al., 1999). Further, cholesterol is removed from HDL 
particles by direct liver uptake or it is transferred to apolipoprotein B-containing 
lipoproteins, i.e. very low density lipoprotein, intermediate density lipoproteins and LDL 
(Tall, 1990; Marcil et al, 1989). In addition to reverse cholesterol transport, HDL has a variety 
of vascular actions that can counteract atherogenesis. HDL contains paraoxonase, an 
enzyme that protects lipoproteins from oxidative modification and it is able to destroy 
oxidized lipids present in oxy-LDL and to hydrolyze lipid peroxides in human 
atherosclerotic lesions. It was observed that lower serum paraoxonase is linked to more 
severe CAD (Aviram et al., 2000;  James et al., 2000; Shih et al., 1998). HDL is thought to 
maintain endothelial function and a low blood viscosity through a permissive action on red 
cell deformability (Kuhn et al., 1991; Epand et al., 1994). It is speculated that HDL may 
downregulate thrombin generation and in this way limit its influence on atherosclerosis 
(Griffin et al., 1999). As regards TG serum levels and CAD burden, according to literature it 
remains uncertain if there is an independent association of TG with coronary 
atherosclerosis. Lipoproteins rich in TG, i.e. very-low density lipoprotein and intermediate 
density lipoprotein (lipoprotein remnants) have been identified in human atherosclerotic 
plaques (Rosenson, 2001). Moreover, hypertriglyceridemia is associated with other 
abnormalities predisposing to the development of atherosclerosis.  
Taken together, these data suggest the role of lipid prophile both in coronary initiation, 
progression and instability. 
4.2 Adiponectin 
Obesity is one of the most common causes of cardiovascular morbidity and mortality 
(Matsuzawa et al., 1995). Abdominal visceral fat accumulation is accompanied by impaired 
glucose tolerance, dyslipidemia, and hypertension, and finally leads to atherosclerotic 
vascular disease. As important molecules linking these diseases and the inflammatory 
response, previous studies have shown the dynamic function of adipose tissue as an 
endocrine organ, releasing various cytokines, adipokines and inflammatory markers, which 
are involved in the development of atherosclerosis (Fortuno et al., 2003).  Notably, adipose 
tissue secretes a variety of bioactive molecules that directly contribute to the development of 
cardiovascular disease (Matsuzawa et al., 1999). Adiponectin is an adipose-specific plasma 
protein, with antiatherogenic and anti-inflammatory properties (Ouchi et al., 1999; 2001). 
and low plasma adiponectin was observed in patients with CAD (Ouchi et al. 2001).  
Additionally, several reports showed an inverse relation between serum CRP and 
adiponectin (Engeli et al., 2003; Yudkin et al., 1999). Otake et al. (Otake et al., 2008) 
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investigated the relation between plasma adiponectin and CRP and coronary plaque 
components in 93 patients with ACS, using VH-IVUS to examine relations among plasma 
CRP, adiponectin, and ratios of each coronary plaque component. They interestingly found 
that plasma adiponectin was significantly lower and plasma CRP was significantly higher in 
patients with than without ACS. There was an inverse relation between serum CRP and 
adiponectin with regard to necrotic core ratio in both culprit and nonculprit lesions in 
patients with ACS. The authors concluded that increased plasma CRP and 
hypoadiponectinemia might be related to the progression of ACS. Additionally, Sawada et 
al. (Sawada et al., 2010) enrolled 50 patients with stable CAD, showing that patients with 
TCFA had significantly lower plasma adiponectin levels than patients without TCFA 
(p<0.0001). Furthermore, the plasma adiponectin levels in patients with multi-vessel TCFA 
were significantly lower than those in patients with single-vessel TCFA (p=0.049). 
Multivariate logistic regression analysis revealed that plasma adiponectin was the strongest 
predictive factor of the presence of TCFA (p=0.0007). Of importance, these data suggest that 
in patients with stable CAD, adiponectin may be a useful biomarker to stratify “vulnerable 
patients” into risk categories. These findings suggest that adiponectin affected plaque 
components, and low plasma adiponectin, a well-known independent risk factor for CAD, 
might enhance the vulnerability of atherosclerotic plaques and vessels, which could lead to 
ACS. 
5. Coagulative/fibrinolysis state  
Coronary thrombosis occurs in most patients with AMI (De Wood et al., 1980) and there is 
also epidemiological evidence indicating the pathogenetic importance of haemostatic 
function in CAD (Meade et al., 1986). The precise role of haemostatic factors in the presence 
of coronary atherosclerosis, however, has not been fully elicited yet. 
5.1 Platelets 
Platelets are actively involved in the inflammatory cascade leading to vascular 
atherosclerosis (Libby & Simon, 2001;; Davi & Patrono, 2007). Platelets are enucleate cells of 
1-2 m length with average life span of 7–8 days, generated by bone-marrow derived 
megakaryocytes after cytoplasmic fragmentation, and play a pivotal role in the process of 
atherosclerosis. Large interest has been directed towards an improved understanding of 
platelet physiology, the assessment of platelet function and the development of improved 
antiplatelet treatment with faster and stronger activity. Patients with stable CAD have 
increased platelet reactivity and circulating monocyte-platelet aggregates (Furman et al., 
1998), which also have been demonstrated early markers of AMI (Furmam et al, 2001). In 
addition, platelet reactivity is progressively increased as a function of the number of 
vascular districts involved by atherosclerosis (cerebral, cardiac, peripheral) (Keating et al., 
2004). Although the platelet count does not appear to predict cardiovascular outcomes 
(Pizzulli et al., 1998) and a larger platelet size may correlate with CAD (Pizzulli et al., 1998) 
and MI. It has been observed a large variability in baseline platelet reactivity and effects of 
antiplatelet therapies, that may potentially due to the variability in platelet size. In fact, 
larger platelets have a greater mass and are both metabolically and enzymatically more 
active than smaller platelets. Indeed, they have a greater prothrombotic potential, with 
higher levels of intracellular thromboxane A2, and TG levels, as well as increased levels of 
procoagulant surface proteins (e.g. P selectin, GpIIb/IIIa). Hemostatically reactive platelets, 
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larger platelets, have more granules and adhesion receptors that have resulted in decreased 
bleeding time showing increased activation. Indeed, platelet aggregability has been directly 
related with systemic atherosclerotic disease (Keating et al., 2004). In addition, the most 
detrimental manifestation of coronary atherosclerotic disease (i.e., myocardial infarction)  is 
mediated by platelet activation (Fitzgerald  et al., 1986). On this basis, numerous therapeutic 
options, targeting platelet aggregability, have been proposed. 
5.1.1 Mean platelet volume 
Mean platelet volume (MPV) has been shown to be an indicator of platelet activation, that 
plays a pivotal role in the pathophysiology of atherosclerotic disease (Tsiara et al., 2003; 
Broadley et al., 2003). It has been reported that elevated values of MPV are associated with 
cardiovascular diseases (Pizzulli et al., 1998; Jagroop & Mikhailidis, 2003). Few and small 
reports have investigated so far the relationship between MPV and the extent of CAD, with 
contrasting results. Also an increase in MPV may be due to the usage of small platelets 
during acute ischemia (Pizzulli et al., 1998). On these grounds, MPV could be accepted as a 
parameter of platelet activity and has become a prognostic factor in CAD. Confirming the 
importance of MPV, several additional reports have demonstrated that MPV was associated 
with impaired myocardial perfusion and clinical outcome after primary angioplasty. De 
Luca et al. (De Luca et al., 2009) measured MPV in 1411 consecutive patients undergoing 
coronary angiography. Significant CAD was defined as stenosis >50% in at least 1 coronary 
vessel. They additionally measured carotid intima-media thickness in 359 patients. The 
relationship between MPV and platelet aggregation was valuated by PFA-100 in 50 
consecutive patients who were not taken any antiplatelet therapy, and in a cohort of patients 
who were on aspirin by PFA-100 (n=161) and Multiplate (n=94). Patients were divided into 
three groups according to tertiles of MPV. Patients with higher MPV were slightly older 
(p=0.038), with larger prevalence of diabetes (p<0.0001), hypertension (p=0.008), previous 
CAD (p=0.041), less often with stable angina (p=0.043) and family history of CAD (p=0.011), 
more often on statins (p=0.012), and diuretics (p=0.007). MPV was associated with baseline 
glycaemia (p<0.0001) and red blood cell count (p=0.056), but inversely related to platelet 
count (p<0.0001). MPV was not associated with the extent of coronary artery disease 
(p=0.71) and carotid intima-media thickness (p=0.9). No relationship was found between 
MPV and platelet aggregation. This study showed that MPV was not related to platelet 
aggregation, the extent of CAD and carotid intima-media thickness. Thus, according to this 
study (De Luca et al., 2009) this parameter cannot be considered as a marker of platelet 
reactivity or a risk factor for CAD. This is the largest study so far conducted to investigate 
the relationship between MPV and CAD.  
Several factors may contribute to explain these findings. The increase in MPV may be a 
process driven by increased production of bone-marrow derived larger circulating 
reticulated platelets within the blood stream (26). Indeed, the MPV has been shown to 
correlate with both megakaryocyte ploidy and with the percentage of circulating reticulated 
platelets (Smith et al., 2002). Furthermore, a positive correlation between thrombopoietin (a 
key thrombopoietic hormone) levels and MPV values has been demonstrated in CAD 
(Senaran et al., 2001).  Thus, larger MPV may not imply higher platelet reactivity, that has 
been shown to be related to the extent and complexity of CAD (Korovesis S, et al., 2000) but 
may be associated with even reduced aggregation since larger platelets may be precursor 
and not fully mature platelets. In fact, De Luca et al. (De Luca et al., 2009) did not observe 
any impact of MPV on platelet aggregation or aspirin resistance. Supporting these data, van 
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der Planken et al. (van der Planken et al., 2000) did not find any relationship between 
platelet prothrombinase activity, a final pathway platelet procoagulant activity of type 1 
diabetic platelets, and MPV. Furthermore, as shown by previous reports, MPV may be 
associated with other prognostic factors, such as smoking, diabetes, obesity, hypertension, 
that may primarily affect the extent of CAD and clinical outcome.  
5.2 Coagulative and fibrinolysis markers 
Previously clinical data support the proposition that activation of the coagulation and the 
platelet system is closely associated with myocardial ischaemia there is little information on 
the relation between the development of coronary atherosclerosis and the haemostatic 
system. 
Nichols et al. (Nichols et al., 1982) did not detect increased concentrations of platelet factor 4, 
B thromboglobulin, and fibrinopeptide A in a group of patients with abnormal coronary 
angiograms without previous MI. Furthermore, Schmitz-Huebner et al. (Schmitz-Huebner et 
al., 1988) analysed blood samples for haemostatic assessment from 225 patients with angina 
pectoris who were admitted to hospital for CAG. Thromboglobulin, platelet factor 3, platelet 
factor 4, factor VII:C, factor VIII:C, von Willebrand factor antigen, activated partial 
thromboplastin time, fibrinogen, antithrombin III, protein C:Ag, plasminogen, and 
antiplasmin were measured before angiography. Of note, patients who had had a MI in the 
two months before the investigation were excluded from the study. Multiple linear 
regression analysis showed that none of the haemostatic variables contributed 
independently to the prediction of an angiographic score that indicated the extent of 
coronary atherosclerosis. There were some significant correlations between haemostatic 
variables and conventional risk factors for CAD. However, the importance of the 
coagulation/fibrinolytic system is highlighted by several autopsic studies that show a high 
prevalence of old plaque disruptions without infarctions. A transient shift in the coagulation 
and anticoagulation balance is likely to result in an acute event. The prolonged presence of 
residual thrombus over a disrupted or eroded plaque will induce smooth muscle migration 
and produce new intima, leading to plaque expansion (Hoffmesister et al., 1995). Autopsic 
studies show that plaque growth is induced by episodic plaque disruption and thrombus 
formation (Holvoet et al., 1997).  Therefore, an active fibrinolytic system may be able to 
prevent luminal thrombosis in some cases of plaque disruption (Hoffmeister et al, 1999). t-
PA, as a crucial factor in fibrinolytic system, plays an important role in the balance between 
coagulative system and fibrinolytic system, which is mainly responsible for the dissolution 
of fibrin clots in the circulation, by converting inactive plasminogen to active plasmin. A 
rapid decline in release of active t-PA is associated with an increasing plaque burden and 
vulnerability. The reduction in acute fibrinolytic capacity reflects impairment of acute t-PA 
release that is likely to involve endothelial cell injury (Munkvad et al., 1990; Gyongyosi et 
al., 2004; Hoffmeister et al., 1998). In the study performed by Wang et al. (Wang et al., 2008), 
the authors aimed at assessing the association between vulnerability of plaque assessed with 
IVUS and plasma levels of fibrinolytic biomarkers in patients with ACS. Eighty-nine 
patients with ACS were enrolled in the study. Blood was collected to measure t-PA levels by 
liquid phase bead flow cytometry. Eighty-nine non-bifurcated lesions (identified by 
coronary angiography) were investigated using IVUS before catheterization. The areas of 
plaque and media were calculated and lesions were classified into two groups: VH-IVUS 
derived VH-TCFA and non-VH-TCFA plaque. Plasma t-PA level in patients with TCFA was 
significantly lower than that with non-TCFA (1489 ± 715) pg/ml vs (2163 ± 1004) pg/ml). 
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Decreased plasma levels of t-PA were associated with plaque vulnerability. Plasma levels of 
t-PA correlated negatively with plaque plus media and necrotic core in plaque in patients 
with acute coronary syndrome. Thus, t-PA may be considered an independent risk factor 
and a powerful predictor of vulnerable plaques. Decreased levels of t-PA may reflect 
instability of atherosclerotic plaques and might therefore serve as noninvasive determinants 
of those at high risk for consequent adverse events. Furthermore, in order to elucidate the 
causes of coronary instability in patients without systemic evidence of inflammation, Niccoli 
et al. (Niccoli et al., 2007) compared rate of episodic production of markers of thrombin 
generation [thrombin–antithrombin complexes (TAT)], of fibrinolysis [plasmin–antiplasmin 
complexes (PAP)], and angiographic severity and extent of coronary atherosclerosis in 
patients with severe UA and high or low systemic levels of CRP. They enrolled 40 
consecutive patients (age 59.7±8.7, 76% males) admitted to coronary care unit with severe 
UA (Braunwald class IIIB. The authors assayed TAT and PAP using commercially available 
ELISA assays and CRP with high sensitivity nephelometry. The evaluation of atherosclerotic 
disease severity and extent was performed according to Bogaty’s score. Patients were 
divided in two groups according to CRP levels: G1=CRP>3 mg/L and G2=CRP<3 mg/L. 
Number of diseased vessels and number of stenoses plus occlusion were similar between 
the two groups (1.8±0.9 in G1 vs 2.2±0.9 in G2, p=NS and 2.6±1.9 in G1 vs 2.7±1.3 in G2, 
p=NS, respectively), as well as extent score and index (8.4±4.5 in G1 vs 9.2±3.1 in G2, p=NS 
and 0.6±0.3 in G1 vs 0.6±0.27 in G2, p=NS, respectively). Episodic activation of thrombin 
generation, as assessed by TAT was more frequent in G1 than in G2 (85% vs 47%, p=0.03). 
Episodic activation of the fibrinolysis was more frequent in G1 than in G2 (80% vs 40%, 
p=0.01). This study demonstrated that patients with severe UA Who have on admission 
high serum levels of CRP are more prone to thrombin generation and fibrinolysis activation 
compared to patients with low admission CRP levels. Severity and extent of CAD was 
similar between patients with high or low CRP levels on admission. Furthermore, in this 
study performed by Niccoli et al. (Niccoli et al., 2007), in patients with systemic evidence of 
inflammation at baseline, episodes of thrombin and plasmin generation were observed more 
frequently than in patients without systemic evidence of inflammation. This is in keeping 
with results of studies (Levi et al., 2006) in the septic patients showing that severe systemic 
inflammation triggers blood coagulation. However, the authors (Niccoli et al., 2007) failed to 
find evidence of a hypercoagulable state or of a more severe coronary atherosclerosis in 
unstable patients without systemic evidence of inflammation. Future studies are warranted 
to investigate other mechanisms of destabilization in patients without systemic evidence of 
inflammation as for instance, mechanical rupture of a thin fibrous cap caused by greater 
mechanical stress. 
5.3 Tissue factor 
Atherosclerotic plaque rupture or fissuring is a key event in the pathogenesis of UA and MI 
(Fuster et al., 1992a,b). The exposure of blood to a procoagulant surface triggers thrombin 
generation, platelet aggregation, and fibrin deposition and leads to thrombus formation that 
can precipitate an acute coronary event. However, atherosclerotic plaques may rupture 
without triggering thrombosis. Necropsy data show that between 9% and 16% of people 
who die suddenly of non-cardiac causes have fissured plaques without thrombosis in their 
coronary arteries, but patients who die of cardiac causes have both thrombosed and non-
thrombosed ruptured plaques (Falk, 1985; Davies et al., 1989). The reasons why some 
ruptured plaques develop thrombosis and others do not are still not known. Tissue factor is 
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a small transmembrane cell surface receptor that mediates cellular initiation of the 
coagulation serine protease cascades (Edgington et al., 1991). In vitro studies have shown 
that tissue factor expression was observed on various cultured and stimulated cell types 
such as monocytes (Jude et al., 1994; Leatham et al., 1995; Barstad et al., 1995). smooth 
muscle cells (Taubman et al., 1993; Maynard et al., 1977), endothelial cells and fibroblasts 
(Green et al., 1971). Tissue factor in the media or the adventitial layer of human normal 
arteries is localized to aid the body in the prevention of blood loss as an initiator of blood 
coagulation (Weiss et al., 1989; Drake et al., 1989; Fleck et al., 1990; Wilcox et al., 1989) Tissue 
factor has recently been shown to be expressed in human coronary atherosclerotic plaque 
from directional atherectomy specimens from patients with stable and unstable coronary 
syndromes (Annex et al., 1995). Therefore, when tissue factor expressed in the coronary 
atherosclerotic plaques is exposed to the blood by the plaque disruption, it may lead to the 
thrombus formation and the occlusion of the related coronary artery. The plaque rupture is 
closely associated with the soft extracellular lipids (Berliner et al., 1995), macrophages (van 
der Wal et al., 1994) matrix-degrading proteases (Libby, 1995) such as interstitial collagenase 
(MMP-1), which degrades two major plaque structural proteins, type I and III collagen, and 
activated mast cells in the shoulder region of the atherosclerotic plaques. Of note, Van der 
Wal et al. (van der Wal et al., 1994) have reported that the macrophages were the 
predominant cells at the immediate site of either rupture or superficial erosion of the fibrous 
cap that contained few smooth muscle cells. However, it is not clear whether the 
macrophages express tissue factor in vulnerable human coronary atherosclerotic plaques in 
patients with unstable angina.  
Kaikita et al. (Kaikita et al., 1997) determined whether macrophages express tissue factor in 
human coronary atherosclerotic plaques. They examined directional coronary atherectomy 
specimens from 24 patients with UA and 23 with stable exertional angina. In these 
specimens, macrophages were detected in 22 (92%) of 24 patients with unstable angina 
versus 12 (52%) of 23 with stable exertional angina (p=0.003). The percentage of macrophage 
infiltration area was significantly larger in patients with unstable angina than in those with 
stable exertional angina (17±3% versus 6±2%, p=0.008). The immunohistochemical double 
staining revealed the expression of tissue factor on macrophages in 18 (75%) of 24 patients 
with unstable angina versus 3 (13%) of 23 with stable exertional angina (p<0.0001). 
Thrombus was identified in 20 (83%) of 24 patients with unstable angina versus 12 (52%) of 
23 with stable exertional angina (p=0.02). Fibrin deposition was mainly observed around 
macrophages expressing tissue factor in the patients with unstable angina. Thus, in this 
study, the authors demonstrated that tissue factor expression on macrophages was more 
frequent in coronary atherosclerotic plaques in patients with UA. Tissue factor expressed on 
macrophages may play an important role in the thrombogenicity in coronary atherosclerotic 
plaques of these patients.  
6. Conclusions and future perspectives  
Cardiovascular disease remains one of the leading causes of morbidity and mortality in the 
developed countries, thus the development of novel therapeutic strategies to reduce 
cardiovascular burden and  risk further than is currently possible is mandatory. Early 
detection of CAD is of paramount importance for initiating aggressive control of risk factors 
(smoking cessation, lipid lowering therapy, weight reduction therapy, aggressive therapy 
for hypertension) and establishing of pharmacologic therapy in order to reduce occurrence 
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of life threatening acute cardiovascular events (anti platelet agents, statins). The use of 
vascular imaging, combined with soluble molecular markers of disease burden, progression 
and activity, can provide crucial information that may help developing new pharmaceutical 
approaches. It is evident from the discussions now ongoing between  industry, government 
regulators, and academia that there is a shared recognition of the need for the application of 
new tools in drug development. This general philosophy, applied to atherosclerosis 
treatment, is critical to addressing the epidemic of CAD. In this regard, the association 
between plaque burden, morphology and activity, as assessed by imaging modalities, and 
levels of circulating biomarkers, assessing lipid metabolism, inflammation, platelets and 
white blood cells activation, and endothelial activation, is an intriguing field. New imaging 
modalities in combination with the development of new biomarkers (bioimaging) may 
significantly improve our understanding and management of patients at risk of coronary 
artery disease and its harmful complications, proving valuable insights into atherosclerotic 
disease progression and the relation to disease activity. In the last decades, an ongoing and 
intense research by different groups and investigators trying to delineate the role of 
different biologically active substances in the pathogenesis of progression of atherosclerotic 
CAD has provided data of paramount importance. Indeed, cardiovascular biomarker 
research efforts have resulted in the identification of new risk factors and novel drug targets, 
as well as the establishment of treatment guidelines, thus recognizing the importance of 
biomarkers in advancing therapies. However, given the complex pathophysiology of 
cardiovascular disease, no single biomarker will likely prove able to provide a universal 
surrogate whereby change observed independently predicts benefit, increased risk, or no 
effect across all drugs and mechanistic targets but the integration of different biomarkers 
looking at different phases of the coronary atherosclerotic disease should be the way 
forward. 
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